QCM
NBIX icon

QRG Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

QRG Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Buy
18,903
+2,384
+14% +$354K 0.03% 378
2026
Q1 		$2.18M Buy
16,519
+305
+2% +$40.5K 0.02% 406
2025
Q4 		$2.3M Sell
16,214
-3,217
-17% -$466K 0.03% 387
2025
Q3 		$2.73M Sell
19,431
-3,150
-14% -$427K 0.03% 330
2025
Q2 		$2.84M Buy
22,581
+2,519
+13% +$289K 0.02% 412
2025
Q1 		$2.22M Buy
20,062
+1,330
+7% +$168K 0.02% 437
2024
Q4 		$2.56M Buy
18,732
+453
+2% +$56K 0.03% 412
2024
Q3 		$2.11M Buy
18,279
+569
+3% +$78K 0.02% 433
2024
Q2 		$2.44M Buy
17,710
+1,832
+12% +$251K 0.03% 380
2024
Q1 		$2.19M Buy
15,878
+1,352
+9% +$185K 0.03% 399
2023
Q4 		$1.91M Buy
14,526
+1,685
+13% +$194K 0.03% 407
2023
Q3 		$1.44M Buy
+12,841
New +$1.35M 0.03% 428

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

QRG Capital Management's NBIX Position: Q2 2026 in Review

QRG Capital Management increased its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, buying an estimated $354K and bringing the position to 18,903 shares worth $3.19M. The position accounts for 0.03% of the portfolio, ranked #378.

QRG Capital Management first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • QRG Capital Management held 18,903 shares of Neurocrine Biosciences worth $3.19M as of Q2 2026.
  • QRG Capital Management bought 2,384 Neurocrine Biosciences shares in Q2 2026, an estimated $354K.
  • Neurocrine Biosciences made up 0.03% of QRG Capital Management's portfolio in Q2 2026, its #378 holding.
  • QRG Capital Management first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.